Effect of gender and apolipoprotein E genotype on response toanticholinesterase therapy in Alzheimer's disease
S.H. Macgowan
Bok Engelsk 1998
| Utgitt | 1998
|
|---|---|
| Omfang | Side 625- 630
|
| Opplysninger | Background. Anticholinesterase therapies offer modest benefit tosubgroups of AD sufferers. However, there has previously been no wayof predicting which patients will respond to any of the drugs.Objective. To discover if gender and/or apolipoprotein E genotype canbe used as predictors of response in the clinical setting,Design. 107 patients from the Bristol Memory Disorders Clinic tookpart in a double-blinded or open label trial of tacrine therapy forbetween 3 and 12 months or an open label trial of galanthaminetherapy for 3 months.Results. After 3 months of therapy, gender was found to be the onlysignificant influence on the number of responders toanticholinesterase therapy. Men had a 73% greater chance ofresponding than women (p = 0.012), While ApoE genotype did not modifyresponse to therapy in the short term, there are indications that itmay affect response over the longer term (up to 12 months), and alsothat the initial advantage of male gender may not be maintained after3 months.Conclusion. Gender is likely to be a more powerful determinant ofoutcome of anticholinesterase treatment than apolipoprotein E statusin the short term. (C) 1998 John Wiley & Sons, Ltd.
|
| Emner |
